HCWB.US HCW Biologics Inc

Healthcare Biotechnology USA Stocks
0.7731 USD
Close of Nov 15, 2026
0.7640 23.94
Market cap
USD 1.73M
P/E
-
P/B
0.23x
ROE
-29.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HCWB.US undervalued?

Graham number

The Graham number of HCW Biologics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HCW Biologics Inc fundamental analysis

No fundamental analysis for HCW Biologics Inc yet.

HCW Biologics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HCW Biologics Inc

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patie…

Full company profile